TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03547804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd/250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
Study: NCT03813706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node dissection
Description: The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
Study: NCT01511419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H7N3
Description: 2 doses of vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 doses of placebo
Study: NCT02435277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Metformin
Description: 1100 mg L Leucine in combination with 125 mg of Metformin BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Metformin
Description: 1100 mg L Leucine in combination with 250mg Metformin BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Metformin
Description: 1100 mg of L Leucine in combination with 500 mg Metformin BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
Study: NCT00818324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 Ophthalmic suspension
Description: Instillation,4times/day,for 52weeks
Study: NCT00604058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis vaccine (IMOVAX)
Description: Fractional dose (1/5th) 0.1 mL, intradermally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis vaccine (IMOVAX)
Description: A full dose, 0.5 mL, intramuscular
Study: NCT03922360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based Financial Incentives
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
Study: NCT03355599

Intervention type: OTHER
Group type: OTHER
Intervention: 3d camera
Description: 3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
Study: NCT03346369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
Study: NCT02005848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01055808

Intervention type: DRUG
Intervention: Insulins
Description: Individual dose and frequency and duration as determined by the treating physician
Study: NCT01980108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water
Study: NCT02644161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dense cranial electroacupuncture stimulation
Description: DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs).
Study: NCT01980108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: water
Study: NCT01727713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Open Label: Once-Daily formulation of aripiprazole flex dose regimine
Study: NCT02667860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis.
Description: Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echelon Endopatch
Description: Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximate Linear Cutter
Description: Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
Study: NCT02426411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03420378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D replacement
Study: NCT02433379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMBLEM S-ICD System
Description: The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
Study: NCT04315376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-Diet Intervention
Description: The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Description: This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
Study: NCT02683525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
Study: NCT02816632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mRI
Description: Neural bases of feedbacks' influence on decision making processes
Study: NCT03732391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG(milligram)/ML
Description: Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
Study: NCT02816632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Galvanic Vestibular Stimulation on decision making processes
Description: Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
Study: NCT00681252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
Study: NCT00870831

Intervention type: OTHER
Intervention: OGTT (Oral Glucose Tolerance Test)
Description: Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide

Intervention type: OTHER
Intervention: OGTT (Oral Glucose Tolerance Test)
Description: Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
Study: NCT03531177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEAL-D
Description: HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants receive usual care from their healthcare team.
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043
Study: NCT02644161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Body acupuncture
Description: Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered.
Study: NCT03949335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL Model ZFR00V
Description: Bilateral implantation with Investigational IOL Model ZFR00V

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL Model ZCB00
Description: Bilateral Implantation with control IOL Model ZCB00
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043
Study: NCT02644161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
Study: NCT01605994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-933043
Study: NCT02403219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Description: Injection of botulinum toxin type A

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline solution injection
Description: Injection of saline solution
Study: NCT02299336

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept
Description: pro re nata (PRN)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Focal Laser
Description: Focal laser administered based on pre-specified criteria
Study: NCT00118066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: calcitriol
Description: Given orally

Intervention type: PROCEDURE
Group type: OTHER
Intervention: observation
Description: No initial intervention
Study: NCT02644161

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antidepressant
Description: Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Least acupuncture stimulation
Description: The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
Study: NCT02080507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Neuronetics rTMS stimulator
Description: In the active group, magnetic power output will be delivered to the subject through the coils.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Neuronetics rTMS stimulator
Description: In the inactive group, no magnetic power output will be delivered to the subject through the coils.
Study: NCT02096588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/cyclophosphamide
Description: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide
Description: The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
Study: NCT02297750

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-wire technique in patients undergoing ERCP with biliary cannulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-wire technique in patients undergoing ERCP with biliary cannulation
Study: NCT04257214

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
Study: NCT01729988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid body excision
Description: This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation.
Study: NCT01415050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 15 times WBV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration
Description: 15 times WBV
Study: NCT03009487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olmesartan 40 mg, Rosuvastatin 20mg
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine/Olmesartan 10/40mg (Combination drug)
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
Study: NCT02170350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation therapy
Description: Use brief mindful meditation practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT00988208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg lenalidomide orally once each day on Days 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 intravenous docetaxel on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 intravenous docetaxel on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg prednisone orally twice daily on each day of the treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg prednisone orally twice daily on each day of the treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo once each day on Days 1-14 of the treatment cycle